Merck & Co., Inc.
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Lagevrio (molnupiravir by Year
Lagevrio (molnupiravir — COVID-19 oral antiviral, Ridgeback alliance) — Worldwide constant-currency (ex-exchange) growth YoY (%) (%)
Merck Lagevrio (molnupiravir: -61.0% in FY2025, down 33.0 pts from a year earlier.
Where the FY2025 figure comes from
“|| Lagevrio | 102 | 83 | 138 | 57 | 380 | 350 | 110 | 383 | 121 | 964 | -53 | -53 | -61 | -61”
Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Reported in Form 8-K Table 3 / 10-K / 10-Q MD&A.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Lagevrio (molnupiravir — COVID-19 oral antiviral, Ridgeback alliance) — Worldwide constant-currency (ex-exchange) growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | -61.0% | -33.0 pts | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | -28.0% | +46.0 pts | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| FY2023 | Dec 31, 2023 | -74.0% | – | Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗ |
Cite this data
StockData. (2026). Merck Lagevrio (molnupiravir (%), annual FY2023–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-lagevrio-ww-exfx-yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.